Market Outlook

The Neuropathic Pain Treatment market was valued at USD 5.83 Billion in 2023 and is projected to grow to USD 8.42 Billion by 2030, with a compound annual growth rate (CAGR) of 5.7% from 2024 to 2030. The Neuropathic Pain Treatment market includes treatments for chronic pain caused by nerve damage or dysfunction, often associated with conditions like diabetes, cancer, and spinal injuries.

As the elderly population grows and the prevalence of chronic illnesses increases, the demand for Neuropathic Pain Treatment therapies is rising. Advances in non-opioid pain management, gene therapy, and targeted treatments are expanding opportunities within the market. Additionally, heightened awareness and improved diagnosis rates, along with a global push for safer, non-addictive alternatives, are contributing to market growth.

However, high treatment costs and potential side effects of existing medications can hinder patient compliance. Strict regulatory barriers, limited access in lower-income regions, and the risk of addiction associated with opioid-based treatments present further challenges. These factors both drive and constrain the Neuropathic Pain Treatment market, underscoring the need for accessible, effective, and safe treatment options to meet the increasing global demand.

Global Neuropathic Pain Treatment Market 2024-2030

Key Insights

The global Neuropathic Pain Treatment market is primarily dominated by North America, which is attributed to high healthcare spending, advanced healthcare infrastructure, and robust research and development (R&D) in pain management therapies. The region's high prevalence of chronic diseases, such as diabetes and cancer, along with significant awareness and access to advanced treatments, drives demand for these therapies. The United States leads in market share within North America, partly due to active initiatives to develop non-opioid pain therapies in response to the opioid crisis.

Europe holds the second-largest market share, fueled by increasing investments in pain management research and a growing elderly population that contributes to a higher incidence of Neuropathic Pain Treatment conditions.

The Asia-Pacific region is expected to experience the fastest growth, driven by rising healthcare awareness, expanding healthcare infrastructure, and a large population base facing increasing incidences of diabetes and other chronic conditions.

In terms of Drug Class, the Anticonvulsants accounted for a major share of 30% in 2023. In the global Neuropathic Pain Treatment market, anticonvulsants hold the largest market share among various drug classes. This dominance is primarily due to their proven effectiveness in treating Neuropathic Pain Treatment, especially in conditions like diabetic neuropathy and postherpetic neuralgia. Commonly prescribed anticonvulsants, such as gabapentin and pregabalin, have seen substantial sales, thanks to their effectiveness and broad regulatory approval.

Following anticonvulsants, serotonin-norepinephrine reuptake inhibitors (SNRIs), such as duloxetine, also capture a significant share of the market because of their ability to provide both pain relief and mood stabilization. Opioids are typically utilized as a secondary treatment option due to concerns regarding dependency and side effects. While tricyclic antidepressants (TCAs) and topical analgesics are also used, their applications are more limited compared to those of anticonvulsants and SNRIs.

Market Dynamics

Rising cases of diabetes, cancer, and other nerve-related conditions are driving demand for Neuropathic Pain Treatment treatments.

The demand for treatments for Neuropathic Pain Treatment is significantly increasing due to the rising prevalence of conditions such as diabetes, cancer, and other nerve-related disorders that commonly lead to this type of pain. Neuropathic Pain Treatment arises from nerve damage or malfunction and is a chronic, often debilitating condition that affects millions of people worldwide.

Diabetes is a major contributor, leading to diabetic neuropathy, especially in long-term cases, and affecting nerve fibers in various parts of the body. Additionally, cancer treatments, particularly chemotherapy, can cause peripheral neuropathy, while other neurological conditions, such as multiple sclerosis, directly affect nerve function and contribute to pain.

As more individuals develop these chronic conditions, the need for effective management of Neuropathic Pain Treatment continues to grow. Improved diagnosis and increased awareness of Neuropathic Pain Treatment also drive this demand, prompting pharmaceutical companies to invest in innovative drugs and therapies to address the needs of this expanding patient population. This trend underscores the importance of advancing accessible and effective pain management solutions globally.

 

The variable nature of Neuropathic Pain Treatment complicates the creation of standard, effective treatments.

Neuropathic Pain Treatment varies significantly from person to person, making it challenging to create standardized and effective treatments. Unlike other types of pain, Neuropathic Pain Treatment stems from nerve damage and can differ in severity, frequency, and response to treatment due to each patient's unique conditions and underlying causes, such as diabetes, multiple sclerosis, or injury. This variability complicates treatment because what may work well for one patient might be ineffective or poorly tolerated by another. Consequently, healthcare providers often resort to a trial-and-error approach to identify suitable therapies, underscoring the need for more personalized and adaptable treatment options in this area.

Key Pointers

Values

Report Focus

Global

Largest Region

North America

Fastest Growing Region

Asia Pacific

Base Year

2023

CAGR % (2024-2030)

5.7%

Forecast Year

2024-2030

Historical Year

2015-2022

Market Size in 2023

USD 5.83  Billion

Market Size in 2030

USD 8.42  Billion

Countries Covered

U.S., Canada, Mexico, Germany, UK, France, Italy, Spain, Turkey, Israel, China, Japan, India, South Korea, Australia, SEA, Brazil, Chile, Argentina, Saudi Arabia, UAE, Qatar, South Africa, Rest of World

Key Driver & Challenges

Rising incidences of diabetes, cancer, and neurological disorders, increasing demand for effective pain management, and advancements in drug development.

High treatment costs, side effects of medications, and lack of awareness, which restrain market growth. 

Segments Covered

By Drug Class, By Application, By Route of Administration, By Distribution Channel

Segmental Analysis

Based on Drug Class, Neuropathic Pain Treatment market is segmented into Tricyclic Antidepressants (TCAs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Anticonvulsants, Opioids, Topical Analgesics, Others. 

The anticonvulsants segment leads the global Neuropathic Pain Treatment market due to their proven effectiveness in treating various types of nerve pain. These medications stabilize electrical activity in the brain and nerve cells, helping to manage the pain signals associated with Neuropathic Pain Treatment. Key anticonvulsants, such as gabapentin and pregabalin, are commonly prescribed for conditions like diabetic neuropathy, post-herpetic neuralgia, and fibromyalgia. Their popularity can be attributed to their effectiveness, relatively favorable side effect profiles, and the ability to be used long-term without a significant risk of dependency.

Moreover, the rising prevalence of Neuropathic Pain Treatment, driven by chronic conditions like diabetes and an aging population, is further increasing the demand for these medications. With ongoing advancements in drug formulations and growing clinical evidence supporting their use, anticonvulsants are expected to remain dominant in the Neuropathic Pain Treatment market.

 

Regional Landscape

Segments

Values

By Drug Class
  • Tricyclic Antidepressants (TCAs)
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • Anticonvulsants
  • Opioids
  • Topical Analgesics
  • Others

By Application
  • Diabetic Neuropathy
  • Chemotherapy-Induced Peripheral Neuropathy (CIPN)
  • Spinal Cord Injury
  • Postherpetic Neuralgia (PHN)
  • Others

By Route of Administration
  • Oral
  • Injectable
  • Topical

By Distribution Channel
  • Hospitals and Clinics
  • Retail Pharmacies
  • Online Pharmacies

In the context of regional analysis, the Neuropathic Pain Treatment market includes North America, Europe, Asia Pacific, South America, and the Middle East and Africa.

The market size of the North America was valued at USD 2.49 Billion in 2023 and is expected to reach USD 3.52 Billion by 2030, with a CAGR of 5.4% during the forecast period. North America is a leading region in the global Neuropathic Pain Treatment market, largely due to the high prevalence of neurological disorders such as diabetes, traumatic brain injuries, and other chronic conditions. 

The United States plays a significant role in this market, with over 2.8% of the population affected by peripheral neuropathy. There is a strong focus on innovative therapies, including FDA-approved drugs like Lyrica, which are used to manage diabetic peripheral neuropathy and chemotherapy-induced neuropathy.

Investments in research and development by major pharmaceutical companies have led to the introduction of non-opioid treatments, which are becoming increasingly popular due to the ongoing opioid crisis. Additionally, improvements in healthcare infrastructure and rising patient awareness regarding chronic pain management options are contributing to the growth of the market in this region. As the demand for effective and safer treatments for Neuropathic Pain Treatment continues to rise, North America remains a key player in the global market expansion.

 

Competitive Landscape

Some of the major companies operating within the Neuropathic Pain Treatment market are: Azurity Pharmaceuticals, Inc., Supernus Pharmaceuticals, Inc., Pfizer Inc. , Viatris Inc. , Almatica, Abbott , Teva Pharmaceutical Industries Ltd.  , Focus Health Group , Amneal Pharmaceuticals LLC , Novartis AG , Accord Healthcare and Others.   

 

Recent Developments

In May 2024- Lexicon Pharmaceuticals, Inc. has selected Medidata, a provider of clinical trial solutions, to deliver services for the Phase 2b clinical study of LX9211, which focuses on managing diabetic neuropathy pain.

In April 2024 – Vertex Pharmaceuticals Incorporated has announced significant advancements in its product Suzetrigine, which is an oral selective NaV1.8 pain signal inhibitor designed for managing diabetic neuropathy pain. This therapeutic could potentially represent the first new class of medicine for both acute and Neuropathic Pain Treatment.

Table of Contents

  1. Global Neuropathic Pain Market Introduction and Market Overview
    1. Objectives of the Study
    2. Global Neuropathic Pain Market Scope and Market Estimation
      1. Global Neuropathic Pain Overall Market Size (US$ Trillion), Market CAGR (%), Market forecast (2024 - 2034)
      2. Global Neuropathic Pain Market Revenue Share (%) and Growth Rate (Y-o-Y) from 2019 - 2034
    3. Market Segmentation
      1. Drug Class of Global Neuropathic Pain Market
      2. Application of Global Neuropathic Pain Market
      3. Route of Administration of Global Neuropathic Pain Market
      4. Distribution Channel of Global Neuropathic Pain Market
      5. Region of Global Neuropathic Pain Market
  2. Executive Summary
    1. Demand Side Trends
    2. Key Market Trends
    3. Market Demand (US$ Trillion) Analysis 2019 – 2023 and Forecast, 2024 – 2034
    4. Demand and Opportunity Assessment
    5. Market Dynamics
      1. Drivers
      2. Limitations
      3. Opportunities
      4. Impact Analysis of Drivers and Restraints
    6. Cost Tear Down Analysis
    7. Key Developments
    8. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
    9. PEST Analysis
      1. Political Factors
      2. Economic Factors
      3. Social Factors
      4. Technological Factors
    10. Production Farm Size by Countries, 2019-2023, Units
    11. Production Farm Size by Companies & Locations, 2019-2023,
      1. Azurity Pharmaceuticals, Inc.
      2. Supernus Pharmaceuticals, Inc.
      3. Pfizer Inc.
      4. Viatris Inc.
      5. Almatica
      6. Abbott
      7. Teva Pharmaceutical Industries Ltd. 
      8. Focus Health Group
      9. Amneal Pharmaceuticals LLC
      10. Novartis AG
      11. Accord Healthcare
      12. Others
  3. Global Neuropathic Pain Market Estimates & Historical Trend Analysis (2019 - 2023)
  4. Global Neuropathic Pain Market Estimates & Forecast Trend Analysis, by Drug Class
    1. Global Neuropathic Pain Market Revenue (US$ Trillion) Estimates and Forecasts, Drug Class, 2019 - 2034
      1. Powdered Neuropathic Pain
      2. Granular Neuropathic Pain
      3. Other Forms
  5. Global Neuropathic Pain Market Estimates & Forecast Trend Analysis, by Application
    1. Global Neuropathic Pain Market Revenue (US$ Trillion) Estimates and Forecasts, Application, 2019 - 2034
      1. Diabetic Neuropathy
      2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
      3. Spinal Cord Injury
      4. Postherpetic Neuralgia (PHN)
      5. Others
  6. Global Neuropathic Pain Market Estimates & Forecast Trend Analysis, by Route of Administration
    1. Global Neuropathic Pain Market Revenue (US$ Trillion) Estimates and Forecasts, Route of Administration, 2019 - 2034
      1. Oral
      2. Injectable
      3. Topical
  7. Global Neuropathic Pain Market Estimates & Forecast Trend Analysis, by Distribution Channel
    1. Global Neuropathic Pain Market Revenue (US$ Trillion) Estimates and Forecasts, Distribution Channel, 2019 - 2034
      1. Hospitals and Clinics
      2. Retail Pharmacies
      3. Online Pharmacies
  8. Global Neuropathic Pain Market Estimates & Forecast Trend Analysis, by Region
    1. Global Neuropathic Pain Market Revenue (US$ Trillion) Estimates and Forecasts, by Region, 2019 - 2034
      1. North America
      2. Europe
      3. Asia Pacific
      4. Middle East & Africa
      5. South America
  9. North America Neuropathic Pain Market: Estimates & Forecast Trend Analysis
    1. North America Neuropathic Pain Market Assessments & Key Findings
      1. North America Neuropathic Pain Market Introduction
      2. North America Neuropathic Pain Market Size Estimates and Forecast (US$ Billion) (2019 - 2034)
        1. By Drug Class
        2. By Application
        3. By Route of Administration
        4. By Distribution Channel
        5. By Country
          1. The U.S.
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in the U.S., 2019-2023
          2. Canada
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in Canada, 2019-2023
          3. Mexico
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in Mexico., 2019-2023
  10. Western Europe Neuropathic Pain Market: Estimates & Forecast Trend Analysis
    1. Western Europe Neuropathic Pain Market Assessments & Key Findings
      1. Western Europe Neuropathic Pain Market Introduction
      2. Western Europe Neuropathic Pain Market Size Estimates and Forecast (US$ Billion) (2019 - 2034)
        1. By Drug Class
        2. By Application
        3. By Route of Administration
        4. By Distribution Channel
        5. By Country
          1. Germany
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in Germany, 2019-2023
          2. Italy
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in Italy, 2019-2023
          3. U.K.
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in U.K, 2019-2023
          4. France
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in France, 2019-2023
          5. Spain
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in Spain, 2019-2023
          6. Benelux
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in Benelux, 2019-2023
          7. Nordics
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in Nordics, 2019-2023
          8. Rest of W. Europe
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in Rest of Western Europe, 2019-2023
  11. Eastern Europe Neuropathic Pain Market: Estimates & Forecast Trend Analysis
    1. Eastern Europe Neuropathic Pain Market Assessments & Key Findings
      1. Eastern Europe Neuropathic Pain Market Introduction
      2. Eastern Europe Neuropathic Pain Market Size Estimates and Forecast (US$ Billion) (2019 - 2034)
        1. By Drug Class
        2. By Application
        3. By Route of Administration
        4. By Distribution Channel
        5. By Country
          1. Russia
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in Russia, 2019-2023
          2. Hungary
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in Hungary, 2019-2023
          3. Poland
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in Poland, 2019-2023
          4. Balkan & Baltics
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in Balkan and Baltics, 2019-2023
          5. Rest of E. Europe
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in Eastern Europe, 2019-2023
  12. Asia Pacific Neuropathic Pain Market: Estimates & Forecast Trend Analysis
    1. Asia Pacific Market Assessments & Key Findings
      1. Asia Pacific Neuropathic Pain Market Introduction
      2. Asia Pacific Neuropathic Pain Market Size Estimates and Forecast (US$ Billion) (2019 - 2034)
        1. By Drug Class
        2. By Application
        3. By Route of Administration
        4. By Distribution Channel
        5. By Country
          1. China
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in China, 2019-2023
          2. Japan
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in Japan, 2019-2023
          3. India
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in India, 2019-2023
          4. Australia & New Zealand
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in Australia and New Zealand, 2019-2023
          5. South Korea
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in South Korea, 2019-2023
          6. ASEAN
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in ASEAN, 2019-2023
          7. Rest of Asia Pacific
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in Rest of Asia Pacific 2019-2023
  13. Middle East & Africa Neuropathic Pain Market: Estimates & Forecast Trend Analysis
    1. Middle East & Africa Market Assessments & Key Findings
      1. Middle East & Africa Neuropathic Pain Market Introduction
      2. Middle East & Africa Neuropathic Pain Market Size Estimates and Forecast (US$ Billion) (2019 - 2034)
        1. By Drug Class
        2. By Application
        3. By Route of Administration
        4. By Distribution Channel
        5. By Country
          1. UAE
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in UAE, 2019-2023
          2. Saudi Arabia
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in Saudi Arabia, 2019-2023
          3. Turkey
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in Turkey, 2019-2023
          4. South Africa
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in South Africa, 2019-2023
          5. Rest of MEA
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in Rest of MEA, 2019-2023
  14. Latin America Neuropathic Pain Market: Estimates & Forecast Trend Analysis
    1. Latin America Market Assessments & Key Findings
      1. Latin America Neuropathic Pain Market Introduction
      2. Latin America Neuropathic Pain Market Size Estimates and Forecast (US$ Billion) (2019 - 2034)
        1. By Drug Class
        2. By Application
        3. By Route of Administration
        4. By Distribution Channel
        5. By Country
          1. Brazil
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in Brazil, 2019-2023
          2. Argentina
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in Argentina, 2019-2023
          3. Colombia
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in Colombia, 2019-2023
          4. Rest of LATAM
            1. By Drug Class
            2. By Application
            3. By Route of Administration
            4. By Distribution Channel
            5. Top Companies Market Share in Rest of LATAM, 2019-2023
  15. Country Wise Neuropathic Pain Market: Introduction
  16. Competition Landscape
    1. Global Neuropathic Pain Market Product Mapping
    2. Global Neuropathic Pain Market Concentration Analysis, by Leading Players / Innovators / Emerging Players / New Entrants
    3. Global Neuropathic Pain Market Tier Structure Analysis
    4. Global Neuropathic Pain Market Concentration & Company Market Shares (%) Analysis, 2023
  17. Company Profiles
    1. Azurity Pharmaceuticals, Inc.
      1. Company Overview & Key Stats
      2. Revenue (USD Million), Sales (Units), and Gross Margin & Market Share, 2019-2023
      3. Product Portfolio & Pricing Analysis
      4. SWOT Analysis
      5. Business Strategy & Recent Developments

* Similar details would be provided for all the players mentioned below 

    1. Supernus Pharmaceuticals, Inc.
    2. Pfizer Inc.
    3. Viatris Inc.
    4. Almatica
    5. Abbott
    6. Teva Pharmaceutical Industries Ltd. 
    7. Focus Health Group
    8. Amneal Pharmaceuticals LLC
    9. Novartis AG
    10. Accord Healthcare
    11. Others
  2. Research Methodology
    1. External Transportations / Databases
    2. Internal Proprietary Database
    3. Primary Research
    4. Secondary Research
    5. Assumptions
    6. Limitations
    7. Report FAQs
  3. Research Findings & Conclusion

No of Tables: 250
No of Figures: 200

Frequently Asked Questions

The average CAGR of Neuropathic Pain Treatment Market is 5.4%.

Anticonvulsants dominated the market with a share of 30% in 2023.

Asia Pacific is estimated to emerge as a fastest growing region with a CAGR of 6.9% during the forecast period 2024-2030.

Market Outlook Report

Buy Now

With Analyst for any Questions